Trade Unlisted is not regulated by the Securities and Exchange Board of India (SEBI). Investments in unlisted securities involve significant risk, including the risk of complete loss of capital. The filing of a Draft Red Herring Prospectus (DRHP) does not guarantee that an Initial Public Offering (IPO) will occur. Unlisted securities are inherently illiquid, price discovery may be limited, and exit opportunities may not materialize.
Trade Unlisted provides news, insights, and general market information for informational and educational purposes only. The content should not be construed as financial, investment, legal, or tax advice. Trade Unlisted does not act as a broker, investment advisor, fiduciary, or intermediary, and does not endorse, recommend, solicit, or validate any investment opportunity. Users are solely responsible for conducting their own independent due diligence before making any financial or investment decisions.
All information is derived from publicly available sources and market observations. While reasonable care is taken in preparing content, Trade Unlisted makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of the information provided. Users should independently verify all information prior to relying on it.
Fintech firm Pine Labs made a solid debut on Dalal Street, listing at ₹242 per share on the NSE—about a 9.5% premium over its issue price of ₹221.
Despite the broader market being relatively subdued, the positive listing underscores investor confidence in its business model.
However, immediately following the listing, the stock dipped to around ₹234, reflecting early trading volatility.
Given these factors, analysts suggest that existing allotment investors may hold for the long term, while new entrants adopt a wait-and-watch approach until the stock settles into a stable trading range.
Comments